Eli Lilly & Co. vs. Pfizer Inc.
Eli Lilly & Co. (LLY) comes out ahead, leading on 6 of 11 compared factors.
Size & Scale
| LLY | PFE | |
|---|---|---|
| Market Cap | $1.11 trillion | $160.96 billion |
| Revenue (TTM) | $79.67 billion | $63.70 billion |
| Net Income (TTM) | $26.71 billion | $4.37 billion |
LLY leads on 3 of 3 size & scale factors.
Valuation
| LLY | PFE | |
|---|---|---|
| P/E Ratio | 42.14 | 36.76 |
| Price / Book | 32.74 | 1.88 |
| Price / Sales | 13.92 | 2.53 |
PFE leads on 3 of 3 valuation factors.
Profitability
| LLY | PFE | |
|---|---|---|
| Net Margin | 33.53% | 6.86% |
| Return on Equity | 78.84% | 5.11% |
LLY leads on 2 of 2 profitability factors.
Dividend
| LLY | PFE | |
|---|---|---|
| Dividend Yield | 0.55% | 6.16% |
| Payout Ratio | 23.23 | 226.32 |
LLY and PFE split the dividend factors evenly.
Risk & Sentiment
| LLY | PFE | |
|---|---|---|
| Short Interest | 1.29% | 0.88% |
PFE leads on 1 of 1 risk & sentiment factors.
Dig deeper: LLY overview, LLY financials, PFE overview, PFE financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.